The status and advances of intravitreal injection in treatment of noninfectious uveitic macular edema
10.3760/cma.j.cn511434-20210428-00214
- VernacularTitle:玻璃体腔注药治疗非感染性葡萄膜炎黄斑水肿的研究现状与进展
- Author:
Jiayi SONG
1
;
Ting CHEN
;
Ming AI
Author Information
1. 武汉大学人民医院眼科中心, 武汉 430060
- Keywords:
Uveitis;
Macular edema;
Intravitreal injections;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2022;38(5):410-414
- CountryChina
- Language:Chinese
-
Abstract:
Noninfectious uveitic macular edema (NIU-ME) is a major cause of visual impairment in patients with uveitis. Intravitreal route can control inflammation rapidly, reduce macular edema, and improve vision with relatively lower doses of the drug. Currently, several intravitreal injection drugs have been used for the treatment of NIU-ME. Cataract and elevated intraocular pressure are the major complications. Due to its efficacy and safety, intravitreal drugs have gradually become an effective alternative to systemic treatment, especially in patients with unilateral disease. However, more studies are needed on drug selection, timing of injection and combination therapy in clinical practice. There are various treatments for NIU-ME, and the ultimate treatment should be individualized based on the severity of the disease, the risk/benefit ratio of each therapy, and the patient's tolerance.
